03:04 AM EDT, 10/06/2026 (MT Newswires) -- Orexo (ORX.ST) intends to raise 250 million kronor through a new issue of shares with preferential rights to bolster its financial position and fund prioritized drug development activities. The Swedish pharmaceutical company said Tuesday that terms, including the subscription price, ratio, and maximum number of shares, will be announced on Nov. 3, with a shareholder vote on the proposed issue at a Nov. 6 extraordinary general meeting. The subscription period is expected from Nov. 12 to Nov. 26. Orexo plans to use the proceeds to advance key development programs for its allergic-reaction drug OX640 and OX390 for respiratory depression due to overdose, while also supporting the regulatory process for its naloxone rescue medication Izipry ahead of potential US approval. A portion of the proceeds will also go to its share of the expected settlement with the US Justice Department and to working capital.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.